Next Gen Immuno-Oncology Virtual Congress-EU/UK [Time Zone- Central European Time]

Registration

Welcome note from MarketsandMarkets

Opening remarks from the Chairman

Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma

Keynote Presentation: Anti-glycan mabs linked to duocarmycin and PBD payloads as potent drug conjugates

Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK

NEXT GEN TARGETED THERAPEUTIC ANTIBODIES AND TUMOR MICROENVIRONMENT

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

Immunogram & Atlas: An Integrated Multi-Omic Approach and Database to Interrogate the Tumor Microenvironment and Guide CDx Development”

Corinne Danan, General Manager, Biopharma, Veracyte

Customized Recombinant Proteins and Antibodies of Broad-Spectrum to Accelerate Immuno-Oncology Research

Linlin Zhang, Technical Specialist, Sino Biological

Networking and One-on-One Meetings on the event portal

Characterizing NSCLC tumor microenvironment using the integrated MultiOmyxTM-RNAscope® workflow

Courtney Todorov, Senior Scientist, NeoGenomics

Two Sides of the same Coin - ImmunoID NeXT and NeXT Liquid Biopsy: Comprehensive Platforms for Tumor Immunogenomics

Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc

Assessing Treatment Benefit in Immuno oncology

Laurence Collette, Principal Statistician, Consulting Services, IDDI

BIG QUESTIONS, SIMPLE SOLUTIONS: Spatial biology in a few and automated steps

Barbara Cahill, Sr. Global Portfolio Manager for Immunohistochemistry, Consumables and Cytology, , Epredia

Complete Genomic Profiling for Global Clinical Trials including bTMB

Reed Selby, Director of Biopharma Business Development, Predicine

Modulation of tumor micro-environment by the oncolytic adenovirus ONCOS-102

Victor Levitsky, Chief Scientific Officer, Targovax

Closing remarks from Chairman

End of Day 1 and One-one-One Networking

Registration

Welcome note from MarketsandMarkets

Opening remarks from the Chairman

Keynote Presentation: Neoantigen Targeted Cancer Immunotherapy in the Clinic

Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

TCR BASED AND CAR-T CELLULAR THERAPY IN IMMUNO-ONCOLOGY

Humanized Mouse Models for Immuno-Oncology Research

Kiave-Yune HoWangYin, PhD , Research and Development Director, Transcure Bioservices

Allogenic Off the Shelf CAR T Cell Therapy

Maurizio Chiriva-Internati, Chairman, CEO, Kiromic

Bioprinted Assembloids: The Next Generation of 3D Tumor Models

Priyanka Koti, Bioink Production Engineer, CELLINK

Networking and One-on-One Meetings on the event portal

Next generation CAR T cells engineered for enhanced safety and efficacy in solid tumors

Melita Irving, Group Leader, Human integrated tumor immunology discovery engine (Hi-TIDe), Ludwig Institute for Cancer Research

Humanized mouse model choices for immuno-oncology drug efficacy and toxicity evaluation

Juan Liang, Scientist, R&D, GemPharmatech

Functional phenomics enabling comprehensive analysis of cancer-immune cell interactions at single-cell resolution

Robert Weingarten, CSO & Co-Founder, Evorion Biotechnologies

Next-Generation Humanized Mice Improve Translation of Novel Immunotherapies

Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen

TNFR2 Antagonism and the Tumor Microenvironment

Russell LaMontagne, President, CEO, Boston Immune Technologies & Therapeutics

Nanopore technology - transforming genomics and transcriptomics

Miten Jain, Assistant Research Scientist, University of California Santa Cruz

Closing Remarks from Chairman

End of Day 2 and One-one-One Networking

Registration

Welcome note from MarketsandMarkets

Opening remarks from the Chairman

Keynote Presentation: Precision Medicine Informed Immuno-Oncology is Transforming Cancer Therapy

ADVANCING PRECISION MEDICINE, BIOMARKERS AND PRECLINICAL DEVELOPMENTS IN IMMUNO-ONCOLOGY

Navigating the Landscape - Curating and Digitizing Public Clinical Trial Data

Mark Gramling, PhD, Director, Oncology, Larvol

T-cell homing in cancer immunotherapy

Ann Ager, Professor, Cellular Immunity and Immunotherapy, Cardiff University

Spatial insights into the complexity of the tumor microenvironment

Bonnie Phillips, P.hd, Director Field Application Scientist, Ultivue

Advantages of vaccines over other Immuno-Oncology products

John Maudsley, CEO, Cancer Vaccines Ltd

Discovery and Development of Novel Antibody Fragment Drug Conjugates for Solid Tumours

Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma

Therapy of advanced non melanoma skin cancers (NMSC) with ICI: What are the advantages and why?

Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene

Advancing immune-oncology drug development with single cell sequencing

Ning Wang, Bioinformatics Lead, Arcus Biosciences

Clinical implementation of SMRT sequencing for Precision Medicine in Immune diseases

Paul ‏Keown, Professor of Medicine, University of British Columbia

Local delivery of anti-PD L1 nanobodies overcomes poor antibody penetration and allows improved blocking of PD-L1 at the tumor site

Jingjing Zhu, Senior Research Scientist, Ludwig Institute for Cancer Research

Closing remarks from Chairman

End of Day 3 and One-one-One Networking